Abstract: A pleuromutilin cinnamic acid ester compound with activities against antibiotic-resistant infections having the following formula (I) R1, R2, R3, R4 and R5 are independently hydrogen, halogen, nitro, cyano, methoxy, trifluoromethyl, benzyloxy, aryl or dimethylamino.

Abstract: The present invention relates to the technical field of medicinal chemistry, and particularly to a method for preparing a 3-tetrazolylmethyl-1,3,5-triazin-2,4-dione compound inhibiting coronavirus 3CL protease activity and use thereof. Specifically, a compound of Formula I, or a pharmaceutically acceptable salt, or an optical isomer, or an isotope-substituted form thereof is provided. The compound effectively inhibits the SARS-CoV-2 3CLpro activity, and is useful in the preparation of a SARS-CoV-2 3CLpro inhibitor to block the replication and transcription of SARS-CoV-2 viruses in patients. The compound prepared in the present invention has high in-vitro safety, and very good prospect of application in the preparation of SARS-CoV-2 3CLpro inhibitors and anti-SARS-CoV-2 drugs.

Abstract: A fracturing fluid may comprise an aqueous based fluid and halloysite nanotubes, wherein the halloysite nanotubes comprise a cargo.

Abstract: The present invention discloses a pleuromutilin derivative containing thiazole-pyridine benzyl quaternary ammonium salt side chain and a preparation method and use thereof and belongs to the field of medicinal chemistry. A pleuromutilin derivative with thiazole-pyridine benzyl quaternary ammonium salt side chain is successfully prepared by structural reconstruction of pleuromutilin and then structural modification with a quaternary ammonium salt compound. This compound synthesis method has the advantages of easily available raw materials, simple operation and high product yield, and is suitable for industrial production. The results of in vitro pharmacological experiments show that the pleuromutilin derivative of the present invention have good antibacterial and anti-mycoplasma activities, as well as good solubility, and these results show that the pleuromutilin derivative is of great value in the development of an anti-pathogenic microorganism drug.

Abstract: A Syringa microphylla seed extract includes the following components by weight based on a total weight of the Syringa microphylla seed extract: 0.4944-0.7142 mg/g of echinacoside, 6.624-7.617 mg/g of oleuropein, 0.4276-0.6309 mg/g of verbascoside, 3.927-4.684 mg/g of syringin, and 4.505-5.250 mg/g of forsythiaside B. A method of preparing the Syringa microphylla seed extract is disclosed. A composition for treating antibiotic-resistant infections that includes the Syringa microphylla seed extract is also disclosed.

Abstract: A pleuromutilin cinnamic acid ester compound with activities against antibiotic-resistant infections having the following formula (I) R1, R2, R3, R4 and R5 are independently hydrogen, halogen, nitro, cyano, methoxy, trifluoromethyl, benzyloxy, aryl or dimethylamino.

Abstract: A method of preparing a hydroxytyrosol sturgeon skin gelatin film with antioxidant activity and Salmonella detection ability includes: (1) mixing a neutral red indicator solution and distilled water at room temperature to obtain a mixture solution, and adding 1 mol/L NaHCO3 solution to the mixture solution until discoloration to obtain an alkaline solution; (2) adding an amount of the alkaline solution obtained in step (1) to a mixture of Sturgeon skin gelatin and distilled water to obtain an alkaline gelatin solution; (3) adding hydroxytyrosol and glycerin and propylene glycol to the alkaline gelatin solution to obtain a hydroxytyrosol gelatin solution, and heating the hydroxytyrosol gelatin solution at 40-70° C.; (4) ultrasonicating the hydroxytyrosol gelatin solution from step (3), placing the hydroxytyrol gelatin solution evenly on a clean plexiglass plate, drying the hydroxytyrol gelatin solution on an ultra-clean worktable to obtain the hydroxytyrosol sturgeon skin gelatin film.

Abstract: Disclosed is a compound of formula I, a pharmaceutically acceptable salt, or a tautomer thereof. formula I. R1, R2, R3 and R4 are independently selected from the group consisting of hydrogen, methyl group, tert-butyl group, methoxy group, difluoromethyl, trifluoromethyl, trifluoromethoxy, nitro, halogen, phenyl and aromatic heterocyclic; R5 is a hydrogen or halogen; and R6 is hydrogen, C1-4 alkane or C1-4 cycloalkane.

Abstract: A compound with anti-drug resistant bacteria activity having the following formula (I): is disclosed. A method of preparing the compound of formula (I) is also disclosed.

Abstract: A compound with anti-drug resistant bacteria activity having the following formula (I): is disclosed. The methods of preparing the compound of formula (I) are also disclosed.

Abstract: A compound of formula I or formula II, a pharmaceutically acceptable salt, or a tautomer thereof is disclosed. The Linker is or and n is 1-6.

Abstract: A compound of formula I or formula II, a pharmaceutically acceptable salt, or a tautomer thereof is disclosed. In formula I and II, n is 1-6.

Abstract: A compound with anti-drug resistant bacteria activity having the following formula (I): is disclosed. The methods of preparing the compound of formula (I) are also disclosed.

Abstract: A method may include: providing a fracturing fluid including, but not limited to, an aqueous base fluid, a friction reducer, and a friction reduction booster; and introducing the fracturing fluid into the subterranean formation.

Abstract: A compound with anti-drug resistant bacteria activity having the following formula (I): is disclosed. The methods of preparing the compound of formula (I) are also disclosed.

Abstract: A compound with anti-drug resistant bacteria activity having the formula (I): (I) is disclosed. The methods of preparing the compound of formula (I) are also disclosed.

Abstract: A compound with anti-drug resistant bacteria activity having the following formula (I): is disclosed. The methods of preparing the compound of formula (I) are also disclosed.

Abstract: A compound with anti-drug resistant bacteria activity having the formula (I): is disclosed. The methods of preparing the compound of formula (I) are also disclosed.

Abstract: A compound with anti-drug resistant bacteria activity having the following formula (I): is disclosed. The methods of preparing the compound of formula (I) are also disclosed.

Abstract: A compound with anti-drug resistant bacteria activity having the following formula (I): is disclosed. The methods of preparing the compound of formula (I) are also disclosed.